AR126649A1 - Formas sólidas de un modulador de hemoglobina - Google Patents
Formas sólidas de un modulador de hemoglobinaInfo
- Publication number
- AR126649A1 AR126649A1 ARP220101301A ARP220101301A AR126649A1 AR 126649 A1 AR126649 A1 AR 126649A1 AR P220101301 A ARP220101301 A AR P220101301A AR P220101301 A ARP220101301 A AR P220101301A AR 126649 A1 AR126649 A1 AR 126649A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- crystalline
- subject
- salt form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188833P | 2021-05-14 | 2021-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126649A1 true AR126649A1 (es) | 2023-11-01 |
Family
ID=82020064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101301A AR126649A1 (es) | 2021-05-14 | 2022-05-13 | Formas sólidas de un modulador de hemoglobina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11851424B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4337659A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520897A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102968809B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN117337285A (cg-RX-API-DMAC7.html) |
| AR (1) | AR126649A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022273787B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021606A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219786A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012156A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202311254A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022241278A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202309517B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024007064A (es) * | 2021-12-10 | 2024-06-20 | Global Blood Therapeutics Inc | Metodos de administracion de un modulador de hemoglobina. |
| EP4727555A1 (en) * | 2023-06-13 | 2026-04-22 | Global Blood Therapeutics, Inc. | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP6426694B2 (ja) * | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
| AR126648A1 (es) * | 2021-05-14 | 2023-11-01 | Global Blood Therapeutics Inc | Métodos para hacer un modulador de hemoglobina |
| MX2024007064A (es) * | 2021-12-10 | 2024-06-20 | Global Blood Therapeutics Inc | Metodos de administracion de un modulador de hemoglobina. |
-
2022
- 2022-05-13 BR BR112023021606A patent/BR112023021606A2/pt unknown
- 2022-05-13 KR KR1020237043235A patent/KR102968809B1/ko active Active
- 2022-05-13 EP EP22729906.2A patent/EP4337659A1/en active Pending
- 2022-05-13 CN CN202280035091.5A patent/CN117337285A/zh active Pending
- 2022-05-13 AR ARP220101301A patent/AR126649A1/es not_active Application Discontinuation
- 2022-05-13 MX MX2023012156A patent/MX2023012156A/es unknown
- 2022-05-13 WO PCT/US2022/029289 patent/WO2022241278A1/en not_active Ceased
- 2022-05-13 AU AU2022273787A patent/AU2022273787B2/en active Active
- 2022-05-13 US US17/744,537 patent/US11851424B2/en active Active
- 2022-05-13 JP JP2023569774A patent/JP2024520897A/ja active Pending
- 2022-05-13 CA CA3219786A patent/CA3219786A1/en active Pending
- 2022-05-13 TW TW111118076A patent/TW202311254A/zh unknown
-
2023
- 2023-10-11 ZA ZA2023/09517A patent/ZA202309517B/en unknown
- 2023-11-01 US US18/499,491 patent/US12473277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024520897A (ja) | 2024-05-27 |
| TW202311254A (zh) | 2023-03-16 |
| KR20240008356A (ko) | 2024-01-18 |
| WO2022241278A1 (en) | 2022-11-17 |
| MX2023012156A (es) | 2023-10-26 |
| CA3219786A1 (en) | 2022-11-17 |
| AU2022273787A1 (en) | 2023-10-26 |
| US11851424B2 (en) | 2023-12-26 |
| ZA202309517B (en) | 2024-06-26 |
| US12473277B2 (en) | 2025-11-18 |
| EP4337659A1 (en) | 2024-03-20 |
| CN117337285A (zh) | 2024-01-02 |
| US20220363674A1 (en) | 2022-11-17 |
| KR102968809B1 (ko) | 2026-05-26 |
| AU2022273787B2 (en) | 2025-04-03 |
| US20240076290A1 (en) | 2024-03-07 |
| BR112023021606A2 (pt) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000373A1 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| AR120703A1 (es) | Formas sólidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-amina de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico | |
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| AR048813A1 (es) | 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos | |
| AR114946A2 (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
| AR078318A1 (es) | Compuestos carbonatos de anti-biopelicula para su uso en composiciones de cuidado oral | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| JP2005506308A5 (cg-RX-API-DMAC7.html) | ||
| BR112018012106A2 (pt) | forma cristalina de inibidor de btk quinase e método de preparação da mesma | |
| UY29766A1 (es) | Formas cristalinas delta y épsilon de mesilato de imatinib | |
| AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| NO954762L (no) | Nye tiazolindindioner og legemiddel inneholdende slike | |
| AR091687A1 (es) | Formas solidas de inhibidores de fosfodiesterasa tipo 5 | |
| DOP2025000064A (es) | Proceso para la preparación de un agente de contraste de gadolinio | |
| RU2019102934A (ru) | Ингибиторы acc для применения в лечении микобактериальных заболеваний | |
| CL2009001146A1 (es) | Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis. | |
| CO2022013595A2 (es) | Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano | |
| ES2529434T3 (es) | Método para tratar neoplasias hematopoyéticas | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| PE20200846A1 (es) | Compuesto de heteroarilo con contenido de nitrogeno y su uso farmaceutico | |
| CO6270318A2 (es) | Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465 | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| JP2016505033A5 (cg-RX-API-DMAC7.html) | ||
| CO2021018154A2 (es) | Compuestos y métodos de uso de los mismos como agentes antibacterianos | |
| CL2025001273A1 (es) | Compuesto bicíclico fusionado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |